TSRO Profile — Tesaro Inc
TESARO is a biopharmaceutical company focused on providing therapies to people facing cancer. Co.'s primary focus is to develop treatments for tumors using various approaches, including small molecules and immuno-oncology antibodies, as monotherapies or in combinations. Co.'s products are: ZEJULA® (niraparib), which is for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI® (rolapitant), a neurokinin, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Co. is evaluating its immuno-oncology anti-tumor agents in combination studies with niraparib and other anti-tumor agents.
|
|
Free TSRO Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.25 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |